Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus carboplatin-pemetrexed versus carboplatin-pemetrexed in EGFR exon 20 insertion-mutated advanced or metastatic non-small cell lung cancer
2020-000633-40Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Amivantamab + carboplatin + pemetrexed with Carboplatin + pemetrexed (2 arms). Primary endpoint: Progression-free survival. Started Sep 2020; status: active.
02
Drugs
amivantamabcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-000633-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000633-40.